Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  brentuximab vedotin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25007, 2013-000232-10, U1111-1154-2250, NMRR-13-1246-18099, REec-2014-0619, NCT01990534
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-005, NCT01100502
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-016, NCT01874054
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG035-0003, 2008-006034-10, NCT00848926
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG035-0004, 2008-006035-12, NCT00866047
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Phase: Phase II
Type: Treatment
Status: Completed
Age: 12 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-006, 2010-019932-11, NCT00947856
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-012, NCT01421667
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-013, NCT01461538
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 12 to 72
Sponsor: Other
Protocol IDs: 11-142, NCT01508312
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-462, NCT01534078
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: Targeted BEACOPP, NCT01569204
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG035-0001, NCT00430846
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-007, NCT01026233
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-008, NCT01026415
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-009, NCT01060904
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-011, 2010-022839-11, NCT01309789
Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01275, E4412, U10CA180820, U10CA021115, NCT01896999
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01273, 13-044, 9467, P30CA008748, U01CA069856, NCT01902160
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25005, 2013-000193-29, NCT01950364
A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Phase: No phase specified
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-010, NCT01196208
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Phase: No phase specified
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LYMNHL0089, SU-06212011-7946, NCT01396070
Start Over